AJOVY® Demonstrates Prevention Efficacy and Safety in Phase 3 Chinese Migraine Trial

A recent Phase 3 clinical trial has demonstrated the effectiveness of AJOVY in significantly decreasing the monthly frequency of migraines among adult patients in China. The study, conducted by Teva Pharmaceuticals, met all predefined primary and secondary endpoints, showcasing AJOVY's superiority over a placebo in reducing migraine days. The drug also exhibited a rapid onset of action and a high responder rate, which is defined as a 50% or more reduction in migraine days, along with a decrease in the use of acute headache medication. Importantly, AJOVY was found to be safe and well-tolerated, with no new safety concerns arising from the study.
In China, migraines affect an estimated 14.3% of the non-elderly adult population, with a significant portion of these individuals not receiving a proper diagnosis or treatment. Teva's commitment to global research aims to address this unmet medical need and to enhance the understanding of treatment innovations like AJOVY. Migraine sufferers often experience severe impairments in their daily activities and quality of life, with a higher likelihood of developing anxiety and depression.
AJOVY, a humanized monoclonal antibody, targets the calcitonin gene-related peptide (CGRP) and has been previously approved for migraine prevention in adults in the U.S. and EU. The Phase 3 trial in China involved 365 participants who were given AJOVY either monthly or quarterly via subcutaneous injections or a placebo. The study's findings are consistent with previous Phase 3 data and further support AJOVY's role as a preventive treatment for migraines.
The most common adverse effects related to AJOVY treatment were injection site reactions, and the open-label phase of the trial is still in progress. The study's additional results are expected to be presented at an upcoming medical conference. Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company dedicated to improving health outcomes through scientific innovation and the development of modern medicines.